Galecto Inc. has announced the acquisition of Damora Therapeutics, expanding its portfolio to include therapies targeting mutant CALR-driven myeloproliferative neoplasms (MPNs). The lead program is a subcutaneous anti-mutCALR monoclonal antibody, developed to address both major forms of mutCALR and aimed at essential thrombocythemia $(ET)$ and myelofibrosis (MF). Clinical proof-of-concept data indicate potential for disease modification and high response rates, with the therapy designed to allow self-administration via an autoinjector every other week. The presentation outlines differentiation from current standard-of-care and late-stage competitors, highlighting the therapy’s ease of use and potential for long-term adherence. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galecto Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.